Mymd Pharmaceuticals (QCLS) Competitors

$4.33 -0.80 (-15.59%)

As of 05/15/2026 04:00 PM Eastern

QCLS vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

Should you buy Mymd Pharmaceuticals stock or one of its competitors? MarketBeat compares Mymd Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mymd Pharmaceuticals include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.

How does Mymd Pharmaceuticals compare to Ainos?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Ainos (NASDAQ:AIMDW) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Mymd Pharmaceuticals had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Mymd Pharmaceuticals and 1 mentions for Ainos. Ainos' average media sentiment score of 1.89 beat Mymd Pharmaceuticals' score of 1.04 indicating that Ainos is being referred to more favorably in the news media.

Company	Overall Sentiment
Mymd Pharmaceuticals	Positive
Ainos	Very Positive

Ainos has higher revenue and earnings than Mymd Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$122.50	N/A
Ainos	$124.16K	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ainos	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ainos' return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-94.03%	-40.68%
Ainos	N/A	N/A	N/A

Summary

Mymd Pharmaceuticals and Ainos tied by winning 4 of the 8 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Alvotech has higher revenue and earnings than Mymd Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$586.32M	N/A	N/A	N/A	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$122.50	N/A

In the previous week, Alvotech and Alvotech both had 2 articles in the media. Alvotech's average media sentiment score of 1.44 beat Mymd Pharmaceuticals' score of 1.04 indicating that Alvotech is being referred to more favorably in the media.

Company	Overall Sentiment
Alvotech	Positive
Mymd Pharmaceuticals	Positive

Alvotech's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	N/A	N/A	N/A
Mymd Pharmaceuticals	N/A	-94.03%	-40.68%

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Alvotech beats Mymd Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Aravive?

Aravive (NASDAQ:ARAV) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

35.8% of Aravive shares are owned by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aravive is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$122.50	N/A

In the previous week, Mymd Pharmaceuticals had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Mymd Pharmaceuticals and 0 mentions for Aravive. Mymd Pharmaceuticals' average media sentiment score of 1.04 beat Aravive's score of 0.00 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aravive	Neutral
Mymd Pharmaceuticals	Positive

Aravive's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Mymd Pharmaceuticals	N/A	-94.03%	-40.68%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aravive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Aravive beats Mymd Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Atlantic Coastal Acquisition Corp. II?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atlantic Coastal Acquisition Corp. II	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Atlantic Coastal Acquisition Corp. II's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-94.03%	-40.68%
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$122.50	N/A
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A

In the previous week, Mymd Pharmaceuticals had 2 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 2 mentions for Mymd Pharmaceuticals and 0 mentions for Atlantic Coastal Acquisition Corp. II. Mymd Pharmaceuticals' average media sentiment score of 1.04 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Mymd Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Mymd Pharmaceuticals	Positive
Atlantic Coastal Acquisition Corp. II	Neutral

Summary

Mymd Pharmaceuticals beats Atlantic Coastal Acquisition Corp. II on 5 of the 7 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Avidity Biosciences?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Avidity Biosciences (NASDAQ:RNA) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Avidity Biosciences had 3 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 5 mentions for Avidity Biosciences and 2 mentions for Mymd Pharmaceuticals. Avidity Biosciences' average media sentiment score of 1.63 beat Mymd Pharmaceuticals' score of 1.04 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Mymd Pharmaceuticals	Positive
Avidity Biosciences	Very Positive

Mymd Pharmaceuticals has higher earnings, but lower revenue than Avidity Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$122.50	N/A
Avidity Biosciences	$18.62M	N/A	-$322.30M	N/A	N/A

Avidity Biosciences has a consensus target price of $66.95, indicating a potential upside of 406.03%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.37

Mymd Pharmaceuticals has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market. Comparatively, Avidity Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Mymd Pharmaceuticals has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-94.03%	-40.68%
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

Summary

Avidity Biosciences beats Mymd Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Mymd Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QCLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QCLS vs. The Competition

Export

Metric	Mymd Pharmaceuticals	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$21.38M	$962.42M	$4.22B	$12.47B
Dividend Yield	N/A	N/A	5.92%	5.28%
P/E Ratio	-0.04	N/A	22.92	25.23
Price / Sales	N/A	249.62	162.71	83.32
Price / Cash	N/A	563.30	50.14	56.04
Price / Book	0.83	64.56	38.26	6.91
Net Income	-$11.63M	-$18.48M	$113.55M	$334.11M
7 Day Performance	N/A	8.00%	2.58%	0.01%
1 Month Performance	N/A	21.04%	4.65%	1.17%
1 Year Performance	N/A	-58.00%	16.53%	30.68%

Mymd Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QCLS Mymd Pharmaceuticals	0.9878 of 5 stars	$4.33 -15.6%	N/A	N/A	$21.38M	N/A	N/A	6	Positive News Earnings Report Analyst Forecast Gap Down
AIMDW Ainos	N/A	$0.10 +1.8%	N/A	-21.7%	$0.00	$124.16K	N/A	40	Positive News Gap Down High Trading Volume
ALVOW Alvotech	N/A	$0.25 -3.8%	N/A	-89.8%	$0.00	$586.32M	N/A	4	Positive News Short Interest Decrease Gap Down
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
ACABW Atlantic Coastal Acquisition Corp. II	N/A	$0.00 flat	N/A	N/A	$0.00	N/A	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QCLS) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

How does Mymd Pharmaceuticals compare to Ainos?

Summary

How does Mymd Pharmaceuticals compare to Alvotech?

Summary

How does Mymd Pharmaceuticals compare to Aravive?

Summary

How does Mymd Pharmaceuticals compare to Atlantic Coastal Acquisition Corp. II?

Summary

How does Mymd Pharmaceuticals compare to Avidity Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

How does Mymd Pharmaceuticals compare to Ainos?

Do insiders and institutionals believe in QCLS or AIMDW?

Does the media refer more to QCLS or AIMDW?

Which has higher earnings and valuation, QCLS or AIMDW?

Do analysts recommend QCLS or AIMDW?

Is QCLS or AIMDW more profitable?

Summary

How does Mymd Pharmaceuticals compare to Alvotech?

Do analysts recommend ALVOW or QCLS?

Which has preferable earnings and valuation, ALVOW or QCLS?

Does the media prefer ALVOW or QCLS?

Is ALVOW or QCLS more profitable?

Do institutionals & insiders have more ownership in ALVOW or QCLS?

Summary

How does Mymd Pharmaceuticals compare to Aravive?

Do insiders & institutionals hold more shares of ARAV or QCLS?

Which has preferable earnings & valuation, ARAV or QCLS?

Does the media favor ARAV or QCLS?

Is ARAV or QCLS more profitable?

Do analysts rate ARAV or QCLS?

Summary

How does Mymd Pharmaceuticals compare to Atlantic Coastal Acquisition Corp. II?

Do analysts recommend QCLS or ACABW?

Do institutionals & insiders hold more shares of QCLS or ACABW?

Is QCLS or ACABW more profitable?

Which has preferable earnings & valuation, QCLS or ACABW?

Does the media refer more to QCLS or ACABW?

Summary

How does Mymd Pharmaceuticals compare to Avidity Biosciences?

Do insiders and institutionals believe in QCLS or RNA?

Does the media favor QCLS or RNA?

Which has stronger earnings and valuation, QCLS or RNA?

Do analysts recommend QCLS or RNA?

Which has more risk & volatility, QCLS or RNA?

Is QCLS or RNA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools